US Patent

US7144884 — Phenyl-piperazine derivatives as serotonin reuptake inhibitors

Method of Use · Assigned to H Lundbeck AS · Expires 2026-06-17 · 0y remaining

Vulnerability score 85/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects compounds represented by the general formula I, useful in treating affective disorders such as depression and anxiety disorders.

USPTO Abstract

The invention provides compounds represented by the general formula I wherein the substituents are defined in the application. The compounds are useful in the treatment of an affective disorder, including depression, anxiety disorders including general anxiety disorder and panic disorder and obsessive compulsive disorder

Drugs covered by this patent

vortioxetine-hydrobromide (VORTIOXETINE HYDROBROMIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1439`	—	vortioxetine-hydrobromide
`U-1439`	—	vortioxetine-hydrobromide
`U-1439`	—	vortioxetine-hydrobromide
`U-1439`	—	vortioxetine-hydrobromide

Patent Metadata

Patent number: US7144884
Jurisdiction: US
Classification: Method of Use
Expires: 2026-06-17
Drug substance claim: Yes
Drug product claim: Yes
Assignee: H Lundbeck AS
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.